Instylla Welcomes Daniel Davis to Its Board of Directors

Author: Owen Jenkins Updated: 04-15-2025 08:15 AM

Instylla Announces Daniel Davis as New Board Member

Instylla, Inc., a clinical-stage company developing cutting-edge solutions for peripheral vascular embolization, has recently appointed Daniel Davis to its Board of Directors. This key decision is expected to further strengthen the company's leadership as it progresses with its innovative medical devices.

Daniel Davis's Experience and Background

Daniel Davis brings over 25 years of extensive experience in the medical device industry. He currently serves as the Chief Strategy Officer at Imperative Care, where he has significantly contributed to the growth and strategic initiatives related to stroke and vascular technologies. His previous roles include serving as Chief Commercial Officer and President for North America at Penumbra, Inc., where he was pivotal in the commercialization efforts of embolization and thrombectomy technologies targeting neurovascular and peripheral vascular applications.

A Warm Welcome to the New Board Member

Amar Sawhney, Chairman and CEO of Instylla, expressed enthusiasm about Daniel's addition to the Board. Amar stated, "We are very pleased to welcome Daniel Davis to the Board at Instylla. His incisive leadership and extensive industry insights align perfectly with our objectives as we work towards the commercialization of our next-generation liquid embolics."

Daniel's Vision for Instylla

Daniel Davis conveyed his excitement about joining the Board at such a transformative time in the company’s trajectory, mentioning, "Instylla has brought forward innovations that have the potential to transform treatment and outcomes, and I am honored to join Amar and the leadership team at this exciting time in the company's growth." He also noted the importance of advancing the Embrace™ Hydrogel Embolic System and bringing the Tembo™ Embolic System to market effectively.

About Instylla, Inc.

Instylla, Inc. was founded in 2017 and is dedicated to developing novel resorbable embolic agents aimed at improving interventional radiology procedures. With a focus on clinical applications in interventional oncology and peripheral vasculature, Instylla strives to create solutions that enhance treatment efficacy. Being a privately held company based in Bedford, MA, it is backed by numerous leading venture capital groups, ensuring solid financial support for its innovative projects.

Future Aspirations of Instylla

The company is on the cutting edge of advancing its medical technologies, aiming to revolutionize the field of interventional radiology. With innovative products like the Embrace™ Hydrogel Embolic System, Instylla is poised to make a significant impact on patient care and treatment outcomes. The leadership team's commitment to combining vast experience and visionary strategies will guide the company as it navigates its exciting journey ahead.

Frequently Asked Questions

Who is Daniel Davis?

Daniel Davis is the newly appointed Board Member at Instylla, bringing over 25 years of experience in the medical device industry.

What role does Daniel Davis hold at Imperative Care?

Daniel is currently the Chief Strategy Officer at Imperative Care, focusing on growth and strategic initiatives in vascular technologies.

What is Instylla, Inc. known for?

Instylla is a clinical-stage company specializing in developing innovative embolic agents for interventional radiology.

What products is Instylla currently focusing on?

Instylla is focused on advancing the Embrace™ Hydrogel Embolic System and the Tembo™ Embolic System.

When was Instylla founded?

Instylla was founded in 2017 and has been dedicated to developing innovative healthcare solutions since its inception.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.